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Abstract
The European Organization for Research and Treatment of Cancer and the Mycosis Study Group (EORTC-MSG) radiological deﬁnitions
of invasive pulmonary aspergillosis (IPA) may lack diagnostic sensitivity. We evaluated applying less restrictive radiological criteria, when
supported by speciﬁc microbiological ﬁndings, to deﬁne IPA in acute myeloid leukaemia (AML), lymphoproliferative diseases (LD) and
allogeneic stem cell transplant (allo-SCT) patients. Overall, 109 consecutive episodes of proven/probable IPA in 56 AML, 31 LD and 22
allo-SCT patients diagnosed from February 2006 through to January 2011 were considered. IPA was diagnosed with EORTC-MSG crite-
ria (control group, 76 patients) or without prespeciﬁed radiological criteria (study group, 33 patients). The latter differed from the
former by the inclusion of patients with pulmonary inﬁltrates not fulﬁlling the three EORTC-MSG IPA speciﬁc ﬁndings of dense, well-cir-
cumscribed lesions with or without halo sign, air crescent sign or cavity. All the analysed clinical and mycological characteristics,
3-month response to antifungal therapy and 1- and 3-month cumulative survival were comparable in the control and study groups in
AML, LD and allo-SCT patients. Seventeen of 33 (51.5%) patients of the study group fulﬁlled EORTC-MSG radiological criteria at subse-
quent imaging performed a median of 15 days (range, 6–40 days) after documentation of the pulmonary infection. Our study seems to
conﬁrm the possibility of revising the EORTC-MSG criteria by extending the radiological suspicion of IPA to less speciﬁc chest comput-
erized tomography scan ﬁndings when supported by microbiological evidence of Aspergillus infection in high-risk haematological patients.
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Introduction
Invasive pulmonary aspergillosis (IPA) is a major cause of
morbidity and mortality in patients, particularly affected by
haematological malignancies and allogeneic stem cell trans-
plant (allo-SCT) [1]. Deﬁnitive aetiological diagnosis of IPA
necessitates tissue microscopic visualization of the character-
istic branching septate hyphae. However, the poor candidacy
of many patients with suspected IPA for invasive diagnostic
procedures has prompted interest in non-invasive means for
diagnosis and most cases of IPA are documented at a level
of probable infection by radiological and microbiological ﬁnd-
ings [2,3]. The need for a standardization of the diagnostic
criteria prompted the European Organization for Research
and Treatment of Cancer (EORTC) and the Mycosis Study
Group (MSG) to develop the consensus deﬁnitions for the
diagnosis of IPA published in 2002 and updated in 2008 [4,5].
These deﬁnitions were developed to facilitate the identiﬁca-
tion of reasonably homogeneous groups of patients for clini-
cal and epidemiological research and to foster
communication between international researchers. According
to the updated EORTC-MSG deﬁnitions, a diagnosis of prob-
able IPA is based on the documentation of at least one of
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three speciﬁc radiological ﬁndings (dense, well-circumscribed
lesions with or without halo sign, air crescent sign or cavity)
associated with Aspergillus isolation from the respiratory
tract and/or positive serum galactomannan (GM) or beta D
glucan (BDG) assay [5]. Although the introduction of deﬁni-
tions for invasive fungal diseases has greatly facilitated the
conduction of clinical trials on diagnostic and therapeutic
modalities for IA, their diagnostic performance in clinical
practice is low when compared with autopsy examination
[6–9]. The application of speciﬁc but not very sensitive diag-
nostic criteria may negatively impact not only the feasibility
of clinical trials, considering the difﬁculties in the recruitment
of eligible patients, but also the epidemiological conscious-
ness of IPA. A recently published retrospective study in
patients affected by multiple myeloma showed that less spe-
ciﬁc radiological images not fulﬁlling the three above ﬁndings,
when supported by microbiological examinations, may be
used to deﬁne an IPA and the authors proposed that the
EORTC-MSG deﬁnitions be revised with the inclusion of a
new category of IPA [10]. The objective of our study was to
expand the above experience in patients with multiple mye-
loma to other patient populations at risk of IPA. In particu-
lar, we focused on acute myeloid leukaemia (AML) patients
undergoing intensive chemotherapy, outpatients with lym-
phoproliferative diseases (LD) undergoing chemo-immuno-
therapy and allo-SCT recipients.
Patients and Methods
This is a retrospective evaluation of a cohort of 109 consec-
utive episodes of proven/probable IPA in patients affected by
AML or LD or submitted to allo-SCT who were cared for at
the Department of Hematology of the Azienda Policlinico
Umberto I of Rome, from February 2006 through to January
2011. Informed consent for the use of clinical data for scien-
tiﬁc purposes had been obtained from the patients. This was
a non-interventional retrospective study and the collection
and storage of data were performed by the investigators
directly involved in patient care using current techniques of
privacy assurance; thus Ethics Committee approval was not
necessary.
At ﬁrst documentation of IPA, cases were included in the
‘control group’ when radiological ﬁndings fulﬁlled the EORTC-
MSG criteria (dense, well-circumscribed lesions with or with-
out halo sign, air crescent sign or cavity) [5] or in the ‘study
group’ when other radiological ﬁndings such as consolidation,
ground-glass opacities and micronodules <1 cm were docu-
mented. In both groups Aspergillus infection was microbiologi-
cally documented by culture isolation of the fungus from the
respiratory tract or by GM assay. GM testing was performed
according to the manufacturer’s instructions (Platelia Aspergil-
lus EIA; Bio-Rad, Marnes-La-Couquette, France). A positive
GM test result was deﬁned as an optical density index of ‡0.5
in serum and ‡1 in bronchoalveolar lavage or sputum.
The following predeﬁned, structured fungal diagnostic
strategies adapted to various categories of patients have
been applied at our centre since 2006.
• AML patients with chemotherapy-induced neutropenia
underwent a clinically driven diagnostic approach as
detailed elsewhere, avoiding GM surveillance during the
whole neutropenia period [11].AML neutropenic patients
with persisting fever after 4 days of antibacterial therapy
or relapsing fever after 48 h of defervescence underwent
an intensive diagnostic work-up (IDWU). IDWU included
three blood cultures, GM serum detection over three
consecutive days, CT scan of the chest and other exam-
inations as indicated.
• In outpatients with LD, pulmonary inﬁltrates suggestive
of an IPA according to the above EORTC-MSG criteria,
as well as other pulmonary inﬁltrates not responding to
antibiotic therapy, were further investigated with cultures
and GM assay from respiratory specimens (bronchoalveo-
lar lavage or sputum) and with GM serum detection.
• Patients submitted to allo-SCT underwent antifungal sur-
veillance until day 100 after transplant or longer in the
event of graft versus host disease (GVHD). Surveillance
was based on the serum detection of GM (twice per
week for hospitalized patients and at least once per week
for outpatients) and on the detection of respiratory tract
colonization by ﬁlamentous fungi (sputum and nasal swab
samples). In the event of a single positive serum GM
assay result or a culture positive for moulds during sur-
veillance or clinical ﬁndings possibly related to an IFD, an
IDWU was performed as detailed above.
Mould-active antifungal therapy (voriconazole, liposomal
amphotericin B, caspofungin or itraconazole) at standard rec-
ommended doses for therapy of aspergillosis was started on
ﬁrst documentation of IPA. All patients in both groups
underwent radiological re-evaluations to monitor the evolu-
tion of the pulmonary infection. Generally, all patients under-
went a ﬁrst repeat CT scan within 3 weeks from the start of
antifungal therapy and subsequently according to clinical
judgement. Response to antifungal therapy was deﬁned as
complete or partial if a >90% or <90% and >50% reduction
in size of the pulmonary lesions was obtained within
3 months from the diagnosis, respectively [12].
Variables considered at diagnosis of IPA or within
3 months from IPA diagnosis included demographic charac-
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teristics, underlying haematological disease, concomitant pul-
monary diseases or respiratory infections other than IPA,
presence of neutropenia (absolute neutrophil count,
ANC <500/cmm) or severe neutropenia (ANC <100/cmm),
duration of neutropenia before and after diagnosis of IPA,
mould-active prophylaxis, radiological and microbiological
ﬁndings, antifungal therapy, response to antifungal therapy
and survival at 3 months. Patients in the ‘study group’ were
monitored for 3 months from IPA diagnosis to eventually
detect the evolution of aspeciﬁc radiological manifestations
to pulmonary lesions speciﬁc of IPA according to EORTC-
MSG deﬁnitions.
The endpoint of this study was to compare the variables
of cases and controls. Categorical data were analysed using
chi-squared or Fisher’s exact tests as appropriate and contin-
uous variables were compared using the t-test. Cumulative
survival curves were calculated using the Kaplan–Meier
method and compared by the log-rank test, taking into
account the date of diagnosis of IPA and the date of death
or last follow-up, censored at 3 months after the diagnosis
of IPA. All analyses were performed using SPSS statistical
software, version 17.0 for Windows (SPSS, Bologna, Italy).
p £0.5 was considered to be statistically signiﬁcant.
Results
During the 5-year period, 109 consecutive episodes of proba-
ble IPA in 56 (51.4%) patients affected by AML and submitted
to intensive chemotherapy, 31 (28.4%) patients affected by
LD and submitted to chemo-immunotherapy and 22 (20.2%)
allo-SCT recipients were considered. The demographic, clini-
cal, radiological and microbiological manifestations, and 1- and
3-month survival of patients are detailed in Table 1.
Overall, 14 (25%) AML patients, 8 (25.8%) LD patients
and 11 (50%) allo-SCT recipients presented at ﬁrst evidence
of IPA with radiological ﬁndings not fulﬁlling the EORTC-
MSG deﬁnitions (study group). No statistically signiﬁcant dif-
ference was observed for all the analysed characteristics,
other than radiological ﬁndings, between the control group
and study group in the three categories of patients. The
radiological ﬁndings more frequently observed at diagnosis of
IPA were macronodules with halo sign in AML patients (23
of 56 patients, 41.1%), and macronodules without halo sign
in both LD and allo-SCT patients (21 of 31 patients, 67.7%,
and nine of 22 patients, 40.9%, respectively). Diagnosis of
IPA was successively proven by histopathological documenta-
tion of fungal tissue inﬁltrate associated with microbiological
evidence of Aspergillus infection, in ﬁve and three patients of
the control group and study group, respectively.
The correlation between ANC and radiological ﬁndings at
onset of IPA in the overall population showed that, out of
73 neutropenic patients (ANC £500/cmm), macronodules
without halo sign, macronodules with halo sign and micro-
nodules were the most frequent predominant ﬁndings,
accounting for 38.4%, 32.9% and 11.0% of cases, respectively,
whereas, out of 37 non-neutropenic patients (ANC >500/
cmm), macronodules without halo sign, consolidations and
micronodules accounted for 51.3%, 27.0% and 8.1% of the
cases, respectively. In particular, macronodules with halo sign
were observed in 24 of 73 (32.9%) neutropenic patients and
in two of 37 (5.4%) non-neutropenic patients (p =0.001).
Voriconazole was the most frequently used primary treat-
ment for IPA and treatment practices did not differ in cases
and controls. The 3-month response to antifungal therapy
and cumulative survival of cases and controls at 1 and
3 months evaluation was comparable in all three groups.
Evolution of radiological ﬁndings in the overall population
of patients in the study groups is detailed in Fig. 1. At a
repeat imaging, radiological ﬁndings speciﬁc to IPA, according
to EORTC-MSG criteria, were documented in 17 of 33
(51.5%) patients [6 of 14 (42.9%) AML patients, 4 of 8 (50%)
LD patients, and 7 of 11 (63.6%) allogeneic SCT patients].
This evolution was documented with CT exams performed a
median of 11 days (range, 5–28 days), 18 days (range,
9–37 days) and 20 days (range, 7–40 days) after their ﬁrst
CT exam in AML, LD and allo-SCT patients, respectively.
Macronodules without halo sign represented the most fre-
quent radiological ﬁnding speciﬁc for IPA at a repeat imaging.
Overall, radiological ﬁndings fulﬁlled the EORTC-MSG crite-
ria in 76 of 109 (69.7%) patients at ﬁrst evidence of IPA and
in 93 of 109 (85.3%) patients when considering repeat imag-
ing performed a median of 15 days (range, 6–40 days) after
documentation of the pulmonary infection.
Discussion
The enrollment of patients with IA in clinical trials may be
difﬁcult when restrictive eligibility criteria are applied. In the
three largest prospective studies on treatment of IA with
voriconazole, liposomal amphotericin B and caspofungin,
respectively [2,3,13], which represented the basis for cur-
rent Aspergillus infections treatment guidelines [14,15], the
recruitment criteria considered the original EORTC-MSG
deﬁnitions [4]. According to these original deﬁnitions any
new pulmonary inﬁltrate, when associated with microbiolog-
ical evidence of Aspergillus infection, was sufﬁcient to deﬁne
a diagnosis of probable IPA. Furthermore, in the studies on
voriconazole and liposomal amphotericin B, 34% of 277
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cases and 60% of 201 cases, respectively, were upgraded to
have probable IPA on the basis of the presence of a halo
or air crescent sign, despite lack of microbiological support,
in order to increase the capacity for recruitment of patients
[1,2]. On the contrary, in the EORTC study on caspofungin
ﬁrst-line therapy for IA [13], patients with possible infection
(i.e. those with a halo sign only, without microbiological
conﬁrmation, or with host factors and clinical signs or
symptoms compatible with IA but again without microbio-
logical conﬁrmation) were allowed to start treatment, but
in the event of lack of upgrade of the cases to proven or
probable IA based on culture or serological tests within
7 days they were discontinued from the efﬁcacy study.
These strict eligibility criteria probably justify the slow
recruitment in this study: 61 evaluable cases from 23 Euro-
pean centres in 2 years.
The deﬁnitions of probable IPA according to the revised
EORTC-MSG criteria [5] are even more restrictive if we
consider that pulmonary inﬁltrates other then macronodules
with or without halo-sign, air crescent sign and cavity are no
longer considered for any diagnosis of pulmonary fungal
infection. Presumably, clinical trials will dramatically suffer
the problem of recruitment of patients with the application
of these revised deﬁnitions, unless extension of eligibility cri-
teria is applied. On the other hand, any subjective modiﬁca-
tion of the standard recruitment criteria would affect the
comparability of the studies against the aim of the EORTC-
MSG efforts to facilitate the identiﬁcation of reasonably
homogeneous groups of patients for clinical and epidemiolog-
ical research.
A recently published retrospective study from the Mye-
loma Institute for Research and Therapy, University of
Arkansas for Medical Sciences, showed that the features of
multiple myeloma patients with probable IPA according to
the revised EORTC-MSG radiological criteria are comparable
to those of patients without speciﬁc radiological ﬁndings
[10]. Out of 116 episodes of IPA, 30% of cases presented
with radiological ﬁndings not fulﬁlling the above speciﬁc EO-
RTC-MSG diagnostic criteria of probable IPA. No signiﬁcant
difference in the host, clinical and mycological characteristics,
as well as in survival, was observed in the two groups. The
authors proposed that the EORTC-MSG deﬁnitions be
revised, with the inclusion of a new category of IA giving a
greater weight to Aspergillus-speciﬁc microbiological criteria,
and suggested expanding their experience in patients with
multiple myeloma to other patient populations at risk of IA.
Our data in AML, LD and allo-SCT patients conﬁrm these
results, although the single-centre experience, the small num-
bers in the subgroups and the retrospective evaluation of
outcomes represent a limitation for any comparison. BothT
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studies suggest that patients with haematological malignancies
at risk of invasive mycoses developing any type of pulmonary
inﬁltrate when associated with microbiological evidence of
Aspergillus infection should be considered to be probably
affected by IPA. This was demonstrated by the comparable
characteristics, response to antifungal therapy and outcome
of patients with and without speciﬁc radiological ﬁndings and
by the evolution in more than 50% of cases of aspeciﬁc pul-
monary inﬁltrates to radiological ﬁndings of IPA according to
the EORTC-MSG criteria, suggesting that these cases might
be an early phase of the disease. The inclusion of these cases
in studies on IA should be considered not only for the
speed, efﬁciency and costs of randomized clinical trials of
novel therapies but also for epidemiological reasons in order
to avoid underestimating infective complications that deserve
proper prevention strategies.
In conclusion, considerable uncertainty and controversy
exists regarding the best method for establishing a diagnosis
of IPA in haematological patients. This is important in clinical
research, considering that a crucial goal when performing a
randomized clinical trial is to limit diagnostic uncertainty
while assuring an adequate enrollment of patients. This was
the spirit of the EORTC-MSG criteria, which have been
deﬁned for research only and not for clinical use. However,
the revised EORTC-MSG deﬁnitions provide highly restric-
tive radiological criteria for diagnosis of probable IPA and
their applicability in future clinical and epidemiological
research might be limited. Our study seems to conﬁrm that
microbiological evidence of Aspergillus infection in high-risk
haematological patients may support the possibility of
extending the radiological suspicion of IPA to less traditional
chest CT ﬁndings. The application of the original EORTC-
MSG deﬁnitions of probable IPA published in 2002 might be
reconsidered [4]. Further study is needed to validate and
standardize new imaging ﬁndings for their use in clinical prac-
tice and enrollment in clinical trials and to support a revision
of the current EORTC-MSG diagnostic criteria of IPA.
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